Axsome intends to use the proceeds from this offering to advance its late-stage pipeline, including funding existing and potential new clinical programs, products, and product candidates, to expand its commercialization efforts, and for other general corporate purposes. SVB Securities is acting as sole bookrunning manager for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AXSM:
- Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
- Axsome Therapeutics Announces Proposed Public Offering of Common Stock
- Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
- Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
- Biotech Alert: Searches spiking for these stocks today